Experimental Pill Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer

Daraxonrasib, an experimental oral KRAS inhibitor, nearly doubled median survival in a 500-patient randomized trial for previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months) and produced fewer s...



























